Affordable Access

deepdyve-link
Publisher Website

Fractionation of Gene Modified Hematopoietic Autografts into Multiple Weekly Infusions Does Not Improve Engraftment in Unconditioned Canine Recipients.

Authors
  • Lutzko, C1, 2
  • Abrams-Ogg, A C3
  • Li, L1
  • Zhao, Y1
  • Lau, K3
  • Kruth, S3
  • Dubé, I D1, 2
  • 1 a Department of Laboratory Medicine , Sunnybrook and Women's College Health Sciences Centre, Faculty of Medicine University of Toronto , Ontario , Canada. , (Canada)
  • 2 b Department of Laboratory Medicine and Pathobiology , Faculty of Medicine University of Toronto , Ontario , Canada. , (Canada)
  • 3 c Department of Clinical Studies , Ontario Veterinary College, University of Guelph , Guelph , Ontario , Canada. , (Canada)
Type
Published Article
Journal
Hematology (Amsterdam, Netherlands)
Publication Date
Jan 01, 1999
Volume
4
Issue
6
Pages
499–503
Identifiers
DOI: 10.1080/10245332.1999.11746477
PMID: 27420745
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Hematopoietic stem cell (HSC) gene therapy will require efficient transfer of genes to HSCs and long term engraftment and proliferation of genetically modified HSCs following adoptive transfer. We evaluated whether fractionation of grafts into 4-5 weekly infusions to non-myeloablated, autologous canine recipients would improve engraftment of genetically modified HSCs. Experimental animals and controls receiving a single infusion had similar levels of engraftment with ∼3-10% of marrow derived progenitors carrying transgene sequences for up to 29 months. There appears to be no improvement of engraftment of genetically modified HSCs in non-myeloablated large animal recipients by dose fractionation.

Report this publication

Statistics

Seen <100 times